Table 3.

MSP profiles in urine sediments of bladder cancer and controls

GenesBladder cancer cases/frequency (%), n = 132Noncancerous urinary lesions case(s)/frequency (%), n = 2395% CI, lower-upper (P; significance as markers)Neurologic diseases case/frequency (%), n = 6Healthy control case/frequency (%), n = 7
SALL377/58.30/0.049.8-66.4 (0.000)0/0.00/0.0
CFTR73/55.30/0.046.8-63.5 (0.000)0/0.00/0.0
ABCC648/36.40/0.028.7-44.8 (0.000)0/0.00/0.0
HPP146/34.80/0.027.3-43.3 (0.000)0/0.00/0.0
BCL236/27.30/0.020.4-35.4 (0.002)0/0.00/0.0
ALX433/25.00/0.018.4-33.0 (0.004)0/0.00/0.0
RUNX343/32.61/4.325.2-41.0 (0.005)0/0.00/0.0
ITGA441/31.11/4.323.8-39.4 (0.005)0/0.00/0.0
RASSF1A47/35.62/8.728.0-44.1 (0.008)0/0.00/0.0
MYOD129/22.00/0.015.8-29.8,(0.008)0/0.00/0.0
MT1A46/34.82/8.727.3-43.3 (0.013)0/0.00/0.0
DRM25/18.90/0.013.2-26.5 (0.027)0/0.00/0.0
BMP3B21/15.90/0.010.6-23.1 (0.045)0/0.00/0.0
CCNA121/15.90/0.010.6-23.1 (0.045)0/0.00/0.0
CDH1322/16.70/0.011.3-23.9 (0.046)0/0.00/0.0
RPRM19/14.40/0.09.4-21.4 (0.078)0/0.00/0.0
MINT117/12.90/0.08.2-19.7 (0.078)0/0.00/0.0
BRCA116/12.10/0.07.6-18.8 (0.131)0/0.00/0.0
PTCHD27/5.30/0.02.6-10.5 (0.595)0/0.00/0.0
TMS14/3.00/0.01.2-7.5 (1.000)0/0.00/0.0
GSTP13/2.30/0.00.8-6.5 (1.000)0/0.00/0.0